ILYM18152 / VLS-101-0001 / Paul BarrResearch Question:
What is the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy
of the novel drug, VLS-101, across a range of dose levels when administered to subjects
with previously treated relapsed or refractory chronic lymphocytic leukemia/small
lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma,
diffuse large B-cell lymphoma, or Richter transformation lymphoma?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics,
immunogenicity, and efficacy of VLS-101, an antibody-drug conjugate (ADC) that targets
receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells. The study
is evaluating VLS-101 in patients with previously treated hematological cancers.
Study Reference #: ILYM18152
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search